Automated buffy coat isolation on Tecan's Freedom EVO(R)
Tecan and IBBL (Integrated BioBank of Luxembourg) have successfully co-developed an automated platform for buffy coat extraction based on a Freedom EVO® 200 workstation.
- (1888PressRelease) January 24, 2013 - Tecan and IBBL (Integrated BioBank of Luxembourg) have successfully co-developed an automated platform for buffy coat extraction based on a Freedom EVO® 200 workstation, relieving scientific staff from performing this time-consuming task, and significantly increasing the yield of DNA.
The process of manually isolating the buffy coat from whole blood is traditionally slow, tedious and very dependent on the skill and dexterity of the technician separating the layers. This lengthy and variable element of sampling has been eliminated by automating the procedure on a Freedom EVO 200 platform, optimized to maximize the yield and quality of the buffy coat and minimize the risk of cross-contamination.
Fay Betsou, Chief of Biospecimen Science at IBBL, explained: "The Freedom EVO's Liquid Handling (LiHa) Arm pipettes the buffy coat layer with very precise orientation and speed, standardizing the process and eliminating technician-to-technician variation. This gives a purer buffy coat product, with less contamination from red blood cells and hemoglobin and a similar distribution of white blood cells. The results are amazing; the DNA yield is 10-15 % higher using the automated process, and the Freedom EVO system can process 24 samples in just 16 minutes. We are very satisfied with the system, and are looking forward to working with Tecan on another biospecimen research project in the near future."
To find out more about Tecan's biobanking solutions, visit www.tecan.com/biobanking
For more information please contact
Tecan Trading AG
Cornelia Kegele / Antonietta Allocca
Seestrasse 103, CH-8708 Männedorf
Tel +41 (0)44 922 81 11, Fax +41 (0)44 922 81 12
info ( @ ) tecan dot com www dot tecan dot com
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2011, Tecan generated sales of CHF 377 million (USD 424 million; EUR 306 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss security number: 1210019).
For more information about IBBL, please visit: www.ibbl.lu.
Press Contact for IBBL
Arnaud d'Agostini
Communications Manager, IBBL
6 rue Nicolas Ernest Barblé
L-1210 Luxembourg
Tel: +352 44 24 64 - 24, Fax: +352 44 24 64 - 64
E-mail: arnaud.dagostini ( @ ) ibbl dot lu
Web: www.ibbl.lu
About IBBL
IBBL (Integrated BioBank of Luxembourg) is an independent, not-for-profit Luxembourg-based biobank dedicated to improving health outcomes for patients by supporting high standards of medical research. IBBL serves as an international centre of excellence in biobanking, and helps to accelerate the introduction of personalised healthcare in Luxembourg. IBBL collects, stores, and analyses biological samples and associated data, which are available to research organisations investigating human diseases. IBBL has built an integrated infrastructure offering biospecimens, data, technologies and biospecimen research to support a successful biomedical research industry in Luxembourg and facilitate rapid translation of discoveries into improved care. IBBL also provides administrative support to the Luxembourg Personalized Medicine Consortium (PMC). With the help of the people of Luxembourg, IBBL catalyses partnerships and supports research that translates today's discoveries into tomorrow's healthcare solutions.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam